Metformin triggers the intrinsic apoptotic response in human AGS gastric adenocarcinoma cells by activating AMPK and suppressing mTOR/AKT signaling

Abstract

Metformin is commonly used to treat patients with type 2 diabetes and is associated with a decreased risk of cancer. Previous studies have demonstrated that metformin can act alone or in synergy with certain anticancer agents to achieve anti-neoplastic effects on various types of tumors via adenosine monophosphate-activated protein kinase (AMPK) signaling. However, the role of metformin in AMPK-mediated apoptosis of human gastric cancer cells is poorly understood. In the current study, metformin exhibited a potent anti-proliferative effect and induced apoptotic characteristics in human AGS gastric adenocarcinoma cells, as demonstrated by MTT assay, morphological observation method, terminal deoxynucleotidyl transferase dUTP nick end labeling and caspase-3/7 assay kits. Western blot analysis demonstrated that treatment with metformin increased the phosphorylation of AMPK, and decreased the phosphorylation of AKT, mTOR and p70S6k. Compound C (an AMPK inhibitor) suppressed AMPK phosphorylation and significantly abrogated the effects of metformin on AGS cell viability. Metformin also reduced the phosphorylation of mitogen-activated protein kinases (ERK, JNK and p38). Additionally, metformin significantly increased the cellular ROS level and included loss of mitochondrial membrane potential (ΔΨm). Metformin altered apoptosis-associated signaling to downregulate the BAD phosphorylation and Bcl-2, pro-caspase-9, pro-caspase-3 and pro-caspase-7 expression, and to upregulate BAD, cytochrome c, and Apaf-1 proteins levels in AGS cells. Furthermore, z-VAD-fmk (a pan-caspase inhibitor) was used to assess mitochondria-mediated caspase-dependent apoptosis in metformin-treated AGS cells. The findings demonstrated that metformin induced AMPK-mediated apoptosis, making it appealing for development as a novel anticancer drug for the treating gastric cancer.

Introduction

Gastric cancer is a leading cause of mortality worldwide according to the World Health Organization, accounting for 754,000 mortalities in 2015 (1). According to the 2017 annual report by the Ministry of Health and Welfare in Taiwan, gastric cancer is the 7th leading cause of cancer-associated mortality. The mortality rate of gastric cancer was 9.8 per 100,000 of the population (2). The major risk factors of gastric cancer are Helicobacter pylori infection, and dietary and environmental factors (3,4). The overall 5-year relative survival rate of patients with gastric cancer in the United States is ~31% (5). Paclitaxel, carboplatin, cisplatin, 5-fluorouracil, capecitabine and leucovorin are recognized as the most effective agents against gastric cancer (6,7). Apart from surgery, no satisfactory chemotherapeutic strategies are currently available for gastric cancer, and novel effective therapies are required to improve gastric anticancer treatment.

Metformin, a biguanide drug, is the first line clinical agent for type 2 diabetes mellitus (T2D) treatment (8,9). The pharmacological mechanism of metformin is to downregulate blood glucose levels to enhance insulin sensitivity in the liver and peripheral tissues (stimulating glucose uptake into muscles and/or increasing fatty acid oxidation in adipose tissue) by activation of adenosine monophosphate (AMP)-activated protein kinase (AMPK) signaling (10,11). In addition, the effectiveness of metformin involves reduced hepatic gluconeogenesis (11,12). The epidemiological studies have suggested that the use of metformin is associated with a decreased incidence of cancer, and improved prognosis and cancer-associated mortality in patients with T2D (13,14). The anticancer effects of metformin have been reported in breast (15,16), colorectal (17), liver (18), cervical (19), endometrial (20), gastric (21), lung (22), ovarian (23), prostate (24), pancreatic (25) and renal (26) cancer. Various studies have demonstrated that the anticancer mechanisms of metformin are mediated via the AMPK/mammalian target of rapamycin (mTOR) cascade, and the signaling is dependent on AMPK activation leading to inhibition of mTOR that represses protein synthesis, cell proliferation, cell cycle progression and apoptotic cell death (27-29). A previous study demonstrated that metformin inhibits the proliferation and metastasis of SGC-7901 and BGC-823 gastric cancer cells by suppressing hypoxia-inducible factor 1α/pyruvate kinase M1/2 signaling (30). Apoptosis (type I programmed cell death) is a tightly regulated biological process (31,32). Anticancer agents that trigger the apoptotic pathway in cancer cells may be of potential clinical use (33). Metformin has been reported to inhibit cell proliferation in human gastric cancer cell lines, including MKN45, MKN47, MKN-28, SGC-7901 and BGC-823, and cancer stem cells (34,35). Additionally, metformin reduces metastasis of human gastric cancer AGS cells by inhibiting epithelial-mesenchymal transition (EMT) in a glucose-independent manner (36). Although the mechanism responsible for the anti-metastatic action of metformin has been investigated, its role of AMPK-mediated apoptotic machinery in gastric cancer cells remains unclear. In the current study, the anti-proliferation effect of metformin cells and underlying apoptotic mechanism was investigated using human gastric cancer AGS cells in vitro.

Materials and methods

Chemicals and materials

Metformin hydrochloride, thiazolyl blue tetrazolium bromide (MTT), In Situ Cell Death Detection kit (fluorescein), compound C, carbobenzoxyvalyl-alanyl-aspartyl fluoromethyl ketone (z-VAD-fmk), and all other chemicals and reagents were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany), unless otherwise stated. All primary antibodies, anti-mouse and anti-rabbit immunoglobulin (Ig)G horseradish peroxidase (HRP)-linked secondary antibodies were obtained from GeneTex International Corporation (Hsinchu, Taiwan). Muse Caspase-3/7 Assay Kit was obtained from Merck KGaA. 2′,7′-Dichlorodihydrofluorescein diacetate (H₂DCFDA) and 3,3′-dihexyloxacarbocyanine iodide [DiOC₆(3)] were obtained from Molecular Probes (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Ham’s Nutrient Mixture F12 medium, minimum essential medium, fetal bovine serum (FBS), L-glutamine, penicillin/streptomycin and trypsin-EDTA were purchased from HyClone (GE Healthcare Life Sciences, Logan, UT, USA). Mitochondria/Cytosol Fractionation Kit was bought from BioVision, Inc. (Milpitas, CA, USA).

Cell culture

The human AGS gastric adenocarcinoma cell line was purchased from the Bioresource Collection and Research Center (Hsinchu, Taiwan) and cultured in Ham’s Nutrient Mixture F12 medium supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. The normal human colon CCD 841 CoN cells (CRL-1790) and embryonic lung fibroblast HEL 299 cells (CCL-137) were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA) and cultured in minimum essential medium containing 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin. Normal 293 cells (CRL-1573) were purchased from the ATCC and maintained in minimum essential medium supplemented with 10% FBS, 0.1 mM non-essential amino acids, 1.0 mM sodium pyruvate, 100 U/ml penicillin and 100 µg/ml streptomycin. All of the cells were maintained at 37°C in a humidified atmosphere incubator with 5% CO₂.

Cytotoxicity assay

The cytotoxic effect of metformin was detected in an MTT assay, as described previously (37). In brief, AGS, CCD 841 CoN, HEL 299 and 293 cells (1×10⁴ cells/well) were cultured in 96-well plates and exposed to various concentrations (10, 20, 30, 40 and 50 mM) of metformin for 12, 24 or 48 h after pretreatment with or without 10 µM compound C (an AMPK inhibitor), or 10 µM z-VAD-fmk (a pan-caspase inhibitor) for 2 h. Following treatments, 10 µl MTT solution (5 mg/ml) was added per well, and the cells were cultured for an additional 3 h. The medium was then removed, and the formation of formazan was solubilized using 100 µl dimethyl sulfoxide. The absorbance was detected using an ELISA plate reader at 570 nm in a spectrophotometer, as previously described (38,39).

Morphological observation

AGS cells (1×10⁵ cells/well) were plated onto 12-well plates and then treated with or without 10, 20, 30, 40 and 50 mM metformin for 12, 24 and 48 h. The cells were subsequently observed and images using a phase-contrast microscope at a magnification of ×200.

Apoptosis analysis by flow cytometry

AGS cells (1×10⁵ cells/ml) were cultured with or without 10, 20, 30 and 40 mM metformin for 48 h. The cells were subsequently washed with PBS and harvested. To detect apoptosis by flow cytometry (BD FACSCalibur Flow Cytometer; BD Biosciences; Becton-Dickinson Co., Franklin Lakes, NJ, USA), the cells were then stained with the In Situ Cell Death Detection Kit, Fluorescein (Sigma-Aldrich; Merck KGaA), following the manufacturer’s instructions. The terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-positive cells were quantified using the BD CellQuest Pro Software version 5.1 (BD Biosciences; Becton-Dickinson and Company), as previously described (38).

Caspase-3/7 activity

AGS cells (5×10⁶ cells/75T flask) were incubated with or without 10, 20, 30 and 40 mM metformin for 48 h. The cells were collected by centrifugation at 400 × g prior to incubation with the working solution provided in the Muse Caspase-3/7 Assay Kit (Merck KGaA), according to the manufacturer’s protocol.

Western blotting

AGS cells (5×10⁶ cells per 75T flask) were incubated with 0, 10, 20 and 30 mM metformin for the indicated period of time (12 or 48 h) following pretreatment with or without 10 µM compound C for 2 h. At the end of the exposure period, the cells were lysed using Trident radioimmunoprecipitation assay lysis buffer (GeneTex International Corporation) to extract total protein. The cytosolic and mitochondrial fractions were prepared via the Mitochondria/Cytosol Fractionation Kit (BioVision, Inc.) according to the manufacturer’s instructions. The protein concentration was determined using the Pierce bicinchoninic acid protein assay kit (Thermo Fisher Scientific, Inc.). A protein sample (40 µg) was loaded in each well of a 10-12% polyacrylamide gel, separated by SDS-PAGE and transferred to the Immobilon-P Transfer membrane (Merck KGaA) for 1 h, as previously described (40). The membrane was blocked with 5% skim milk in Tris-buffered saline with 0.1% Tween-20 (TBST) and incubated with the following primary antibodies (GeneTex International Corporation): Phospho (p)-AMPK (cat no. GTX52341), AMPK (cat no. GTX112998), p-protein kinase B (AKT; cat. no. GTX28932), AKT (cat. no. GTX121937), p-mTOR (cat. no. GTX50258), mTOR (cat. no. GTX101557), p-ribosomal protein S6 kinase B1 (p70S6K; cat. no. GTX50304), p70S6K (cat. no. GTX103174), p-extracellular signal regulated kinase (ERK; cat. no. GTX59568), ERK (cat. no. GTX59618), p-c-Jun N-terminal kinase (JNK; cat. no. GTX52326), JNK (cat. no. GTX52360), p-p38 (cat. no. GTX48614), p38 (cat. no. GTX110720), p-Bcl-2-associated agonist of cell death (BAD; Ser136; cat. no. GTX50136), BAD (cat. no. GTX130108), B cell lymphoma-2 (Bcl-2; cat. no. GTX100064), cytochrome c (cat. no. GTX108585), apoptotic protease-activating factor-1 (Apaf-1; cat. no. GTX22000), caspase-9 (cat. no. GTX112888), caspase-3 (cat. no. GTX110543), caspase-7 (cat. no. GTX22301; all 1:1,000 dilution), β-actin (cat. no. GTX109639; 1:5,000 dilution), GAPDH (cat. no. GTX100118; 1:5,000 dilution), and cytochrome c oxidase subunit IV isoform 1 (COX IV; cat. no. GTX114330; 1:2,000 dilution) at 4°C overnight. The next day, the membrane was washed with TBST and incubated with the appropriate anti-rabbit (cat. no. GTX213110-01) and anti-mouse (cat. no. GTX213111-01) IgG HRP-linked antibodies (1:10,000 dilution) for 1 h at room temperature. An enhanced chemiluminescence kit (Immobilon Western Chemiluminescent HRP substrate; Merck KGaA) was used to visualize protein bands, and protein band densitometry was performed using ImageJ software (version 1.47; National Institutes of Health, Bethesda, MD, USA).

Measuring reactive oxygen species (ROS) and the mitochondrial membrane potential (ΔΨm) via flow cytometry

AGS cells (2×10⁵ cells/ml) seeded in 12-well plates were exposed to 0, 10, 20, 30 and 40 mM metformin for 48 h. Subsequently, the cells were harvested and centrifuged at 400 × g for 5 min, and the cell pellet was suspended in 500 µl H₂DCFDA (an ROS indicator dye, 10 µM) or DiOC₆(3) (a ΔΨm probe, 50 nM) staining solution at 37°C for 30 min. The cells were then analyzed using flow cytometry (BD FACSCalibur Flow Cytometer; BD Biosciences; Becton-Dickinson Co.), as previously described (40,41).

Statistical analysis

All results are presented as the mean ± standard deviation of triplicates. The data were statistically analyzed by one-way analysis of variance followed by Dunnett’s test using SPSS software version 16.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Metformin is cytotoxic to human gastric cancer AGS cells

After cells were treated with 10, 20, 30, 40 and 50 mM metformin for 12, 24 and 48 h, the MTT assay was used to analyze cell viability. The results demonstrated that metformin significantly reduced cell viability after incubation with 20 mM metformin for 12 h; furthermore, the reductions of viability were time- and concentration-dependent (Fig. 1). The cells were treated with metformin prior to morphological characterization. The marked morphologic alterations (such as cell shrinkage, nuclear condensation, membrane blebbing and rounding) were present in a time- and concentration-dependent manner in AGS cells (Fig. 2). Thus, metformin suppressed AGS cell growth via induction of apoptotic death. Additionally, the data demonstrated that metformin (0, 10, 20, 30 and 50 mM) after exposure for 48 h had no significant effect of the viability of normal colon CCD 841 CoN cells (Fig. 3A), embryonic lung HEL 299 cells (Fig. 3B) and 293 cells (Fig. 3C). This suggested that metformin may have lower toxicity in normal cells (CCD 841 CoN, HEL 299 and 293 cells) compared with cancer cells.

Figure 1.

Effect(s) of metformin on the viability of AGS cells. The cells were exposed to 0, 10, 20, 30, 40 and 50 mM of metformin for 12, 24 and 48 h. The viability of AGS cells was detected by the MTT assay. The values are presented as the mean ± standard deviation of triplicates within three representative experiments. ^*P<0.05 vs. untreated control.

Figure 2.

Effect(s) of metformin on apoptotic morphological changes of AGS cells. The cells were treated with or without 10, 20, 30, 40 and 50 mM of metformin for 12, 24 and 48 h. The cells were observed and imaged via a phase-contrast microscope at ×200 magnification. Arrows indicate apoptotic AGS cells.

Figure 3.

Effect(s) of metformin on the viability of normal cells. (A) Normal human colon CCD 841 CoN cells, (B) embryonic lung HEL 299 cells and (C) 293 cells were treated with 0, 10, 20, 30 and 50 mM of metformin for 48 h. The cell viability was determined via the MTT assay. The values are presented as the mean ± standard deviation of triplicates within three representative experiments.

Metformin promotes apoptosis of AGS cells

Following treatment of AGS cells with 10, 20, 30 and 40 mM metformin for 48 h, a TUNEL assay was used to detect DNA breaks, which are a direct apoptotic response. The results demonstrated that metformin at 20, 30 and 40 mM concentration-dependently produced double-stranded DNA fragmentation (a unique biochemical hallmark of apoptosis) and enhanced the number of TUNEL-positive cells (Fig. 4A), indicating that metformin induces AGS cell apoptosis. To determine whether caspase-3/7 are involved in the metformin-induced apoptosis, caspase-3/7 activity was analyzed using a Muse Caspase-3/7 Assay kit. The data indicated that metformin (20, 30, and 40 mM) significantly enhanced the activity of caspase-3/7 in a concentration-dependent manner (Fig. 4B). These findings demonstrate that the ability of metformin to trigger apoptosis of AGS cell may be caspase-3/7-dependent.

Figure 4.

Effect(s) of metformin on apoptotic evidence and caspase-3/7 activity of AGS cells. The cells were incubated with 0, 10, 20, 30 and 40 mM of metformin for 48 h. (A) TUNEL-positive cells were determined by flow cytometry, as described in the Materials and Methods section. (B) Caspase-3/7 activities were analyzed via Muse Caspase-3/7 Assay Kit. The values are presented as the mean ± standard deviation of triplicates. ^*P<0.05 vs. untreated control. TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling.

AMPK pathway contributes to metformin-induced cytotoxicity and apoptosis in AGS cells

AMPK and AKT/mTOR signaling are usually involved in the regulation of cell proliferation and apoptosis (42). AGS cells were treated with 10, 20 and 30 mM metformin for 12 h, or pretreated with or without 10 µM compound C (an AMPK inhibitor) for 2 h prior to metformin exposure. The findings indicated that metformin stimulated phosphorylation of AMPK at Thr172, but there was no alteration in AMPK expression in AGS cells (Fig. 5A). To confirm whether the AMPK pathway has a key molecular role in metformin-treated AGS cells, an AMPK inhibitor, compound C, was applied, and the level of p-AMPK and cell viability were analyzed by western blotting and an MTT assay, respectively. The data demonstrated that compound C suppressed phosphorylation of AMPK (Fig. 5B) and significantly reversed the effect of metformin on cell viability compared with metformin treatment only (Fig. 5C). Thus, metformin-induced apoptosis is mediated via modulated AMPK signaling in AGS cells. To further clarify the downstream signaling involved, cells were treated with metformin and harvested for western blot analysis to detect the phosphorylation of AKT (p-AKT), mTOR (p-mTOR), and p70S6K (p-p70S6K). The results demonstrated that metformin decreased the phosphorylation of AKT, mTOR, and p70S6K, whereas metformin did not affect the protein expression in AGS cells (Fig. 5D). These data indicate that metformin enhances apoptosis potentially by targeting AMPK and AKT/mTOR pathway in AGS cells.

Figure 5.

Effect(s) of metformin on AMPK signaling and its downstream molecules of AGS cells. (A) Cells were exposed to 0, 10, 20 and 30 mM metformin for 12 h and protein levels of p-AMPK and AMPK were detected. (B) Cells were cultured without or with 10, 20 and 30 mM metformin for 12 h following pre-incubation with or without 10 µM compound C (an AMPK inhibitor) for 2 h and protein levels of p-AMPK and AMPK were detected. (C) Cells were treated without or with 30 mM metformin for 48 h after pre-incubation with or without 10 µM compound C for 2 h. Cell viability was estimated by the MTT assay. The values are presented as the mean ± standard deviation of triplicates. ^*P<0.05 vs. metformin-treated only. (D) Cells were treated without or with 10, 20 and 30 mM of metformin for 12 h and protein levels of p-AKT, AKT, p-mTOR, mTOR, p-p70S6K and p70S6K were determined by immunoblot analysis. β-actin was an internal loading control. p-, phospho; AMPK, adenosine monophosphate-activated protein kinase; AKT, protein kinase B; mTOR, mammalian target of rapamycin; p70S6K, ribosomal protein S6 kinase B1.

Metformin inhibits mitogen-activated protein kinase (MAPK) signaling in AGS cells

To assess whether MAPKs (ERK, JNK and p38) contribute to metformin-induced apoptosis, the cells were exposed to metformin and MAPK proteins were detected via western blot analysis. MAPK signals are essential for induction of apoptosis (43,44). Treating AGS cells with metformin markedly attenuated the phosphorylation of ERK, JNK and p38 (Fig. 6), with no obvious alterations in ERK, JNK and p38 MAPK protein expression. The results demonstrate that the apoptotic mechanism of metformin may involve ERK, JNK, and p38 MAPK-regulated pathways in AGS cells.

Figure 6.

Effect(s) of metformin on ERK, JNK and p38 pathways of AGS cells. The cells were incubated with 0, 10, 20 and 30 mM of metformin for 12 h, and whole-cell lysates were then collected. Cell fractions were individually probed with anti-p-ERK, anti-ERK, anti-p-JNK, anti-JNK, anti-p-p38 and anti-p38 by western blotting analysis. β-Actin was an internal loading control. p-, phospho; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase.

Metformin promotes ROS production and ΔΨm in AGS cells

To determine whether metformin-induced apoptosis is mitochondria-dependent, ROS production and the ΔΨm were measured in AGS cells. The cells were treated with metformin at various concentrations (10, 20, 30 and 40 mM) for 48 h. The levels of ROS production and ΔΨm were measured using the specific fluorochromes H₂DCFDA and DiOC₆(3), respectively, via flow cytometry. The results revealed that metformin increased the production of ROS (Fig. 7A) and decreased the ΔΨm (Fig. 7B) in AGS cells. Furthermore, these effects were concentration-dependent.

Figure 7.

Effect(s) of metformin on ROS production and ΔΨm in AGS cells. Cells were incubated with or without 10, 20, 30 and 40 mM of metformin for 48 h. (A) ROS levels were measured by staining with 2′,7′-dichlorodihydrofluorescein diacetate and (B) the level of ΔΨm was assessed with 3,3′-dihexyloxacarbo-cyanine iodide by flow cytometry. The values are presented as the mean ± standard deviation of triplicates. ^*P<0.05 vs. untreated control. ROS, reactive oxygen species; ΔΨm, mitochondrial membrane potential.

Metformin induces apoptosis via the intrinsic signaling pathway in AGS cells

To determine the effect of metformin on apoptosis, the expression of Bcl-2 family proteins and mitochondria-mediated proteins were analyzed in metformin-treated AGS cells. Western blot analysis indicated that metformin treatment reduced the phosphorylation of BAD and expression of Bcl-2, but metformin induced total BAD expression in AGS cells (Fig. 8A). Furthermore, metformin increased the protein expression of Apaf-1 (Fig. 8B) and reduced the expression of pro-caspase-9, pro-caspase-3 and pro-caspase-7 expression (Fig. 8C) in AGS cells. Furthermore, metformin caused an increase in cytochrome c in cytoplasmic extracts (Fig. 8D); however, mitochondrial cytochrome c levels were decreased in AGS cells (Fig. 8D). Notably, z-VAD-fmk, a pan-caspase inhibitor, significantly abrogated the effect of metformin on viability compared with metformin-treated cells (Fig. 8E), suggesting that mitochondria-mediated caspase-dependent apoptosis may be required for the cytotoxic effect of metformin on human gastric adenocarcinoma AGS cells (Fig. 9).

Figure 8.

Effect(s) of metformin on mitochondria-mediated caspase-dependent apoptotic signaling of AGS cells. The cells were treated with 0, 10, 20 and 30 mM of metformin for 48 h, and whole-cell lysates and mitochondrial and cytosolic fractions were then harvested. Protein levels of (A) p-BAD, BAD and Bcl-2, (B) Apaf-1 and (C) caspase-9, caspase-3 and caspase-7 signals were determined by western blot analysis. β-actin was an internal loading control. (D) The cytosolic (top) and mitochondrial (bottom) fractions were used to determine for cytochrome c translocation by western blot analysis. GAPDH and COX IV were internal loading controls. (E) Following pre-incubation with or without 10 µM z-VAD-fmk (a pan-caspase inhibitor) for 2 h, the cells were exposed to 30 mM metformin for 48 h. Cell viability was assessed using the MTT assay. The values are presented as the mean ± standard deviation of triplicates. ^*P<0.05 vs. metformin-treated only. p-, phospho; BAD, Bcl-2-associated agonist of cell death; Bcl-2, B-cell lymphoma-2; Apaf-1, apoptotic protease-activating factor-1; z-VAD-fmk, carbobenzoxyvalyl-alanyl-aspartyl fluoromethyl ketone.

Figure 9.

Schematic diagram of an integrated circuit regarding that AMPK, AKT/mTOR, and apoptosis-related molecular machinery caused by metformin in human gastric adenocarcinoma AGS cells. p-, phospho; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; AMPK, adenosine monophosphate-activated protein kinase; mTOR, mammalian target of rapamycin; p70S6K, ribosomal protein S6 kinase B1; AKT, protein kinase B; ROS, reactive oxygen species; BAD, Bcl-2-associated agonist of cell death; Bcl-2, B-cell lymphoma-2; ΔΨm, mitochondrial membrane potential; Cyto. c, cytochrome c; Apaf-1, apoptotic protease-activating factor-1; z-VAD-fmk, carbobenzoxyvalyl-alanyl-aspartyl fluoromethyl ketone.

Discussion

Metformin, an oral biguanide agent that was FDA-approved in 1957, has been used as a safe and cost-efficient treatment for T2D worldwide (45,46). Numerous studies have indicated that long-term administration of metformin reduces the risk of various types of cancer, including breast, colon and endometrial cancer, and glioma (13-17,20,47). Recently, Li et al (48) demonstrated that metformin can increase the survival rate of diabetic patients with gastric cancer. Previous studies have demonstrated that metformin inhibits cell proliferation and induces cell death in various types of cancer cells, including HepG2 hepatoma cells (49), SKOV3, A2780 and ES2 ovarian cancer cells (50,51), paclitaxel-resistant A2780-PR and cisplatin-resistant ACRP cells (52), B16F10 melanoma cells (53), Dami and MEG-01 megakaryoblastic cancer cells (54), and CAL 27, CAL 33, and UMSCC47 head and neck carcinoma cells (55). Furthermore, metformin also suppresses the cell metastasis of MG63 and U-2 OS osteosarcoma cells (56), SiHa and HeLa cervical cancer cells (57), and EC109 esophageal squamous cells carcinoma cells (58). In addition, synergistic interactions with metformin enhance antitumor activities; for example, sirolimus in colorectal cancer cells (59), chrysin in breast cancer (60), quercetin in prostate cancer cells (24), rapamycin in pancreatic cancer cells (61), vincristine in leukemia cancer cells (62), curcumin in hepatocellular carcinoma cells (63), cisplatin in gallbladder cancer cells (64). Metformin at 10-100 mM has been reported to dose- and time-dependently inhibit cell proliferation in AGS cells in low-and high-glucose conditioned media (36). In the current study, the results revealed that treatment with 50 mM metformin significantly inhibited the viability of AGS cells (Video S1). These results are in accordance with those from a study by Valaee et al (36), indicating that metformin suppresses the proliferation and viability of AGS cells. An in vivo study also demonstrated that metformin did not cause apparent toxicity in nude mice bearing with hepatocellular carcinoma tumors (65). The findings also revealed that metformin has no effect on viability in normal cells (human colon CCD 841 CoN, embryonic lung HEL 299 and 293 cells).

AMPK is a serine/threonine protein kinase (10,11). AMPK signaling is a cellular energy and nutrient sensor, and also has an essential role in metabolic pathways (27,28). AMPK activation inhibits protein synthesis and cell proliferation (11,28). Furthermore, activation of the AMPK signaling inhibits tumor growth (27,28). Metformin suppresses the respiratory complex I, which increases the adenosine diphosphate/adenosine triphosphate (ATP) and AMP/ATP ratios, and attenuates of ATP production and oxidative phosphorylation, resulting reduced cellular ATP and activation of AMPK (10,12). Zakikhani et al (66) demonstrated that metformin attenuates the proliferation of breast cancer cells through the activation of AMPK, causing the inhibition of mTOR signaling. Metformin activates the expression of AMPK and inhibits phosphorylation of mTOR, downstream p70S6K, and eIF4E-binding proteins (67). The present study demonstrated that metformin-induced apoptosis was accompanied by upregulation AMPK Thr172 phosphorylation, and downregulation of AKT (Ser473), mTOR (Ser2448) and p70S6K (Ser424) phosphorylation. The data also demonstrated that attenuation of AMPK signaling using an AMPK inhibitor (compound C) abrogated the effects of metformin on the viability of AGS cells.

MAPKs include three main molecules, ERK, JNK and p38, which have various biological functions, including apoptotic mechanisms, cell cycle regulation and cell survival (43,44). Activation of AMPK signaling and the attenuation of ERK signaling contribute to the antitumor effects of metformin in MCF-7 breast cancer cells (68). Furthermore, the inhibitory effect of metformin on MAPK activity is involved in protection against atherosclerosis (69). Lu and Xu (70) demonstrated that ERK1/2 activation can inhibit cell apoptosis via modulation of tumor necrosis factor, Fas ligand, radiation stress, hypoxia and response to chemotherapeutic agents. Potapova et al (71) indicated that inhibition of JNK2 activity can also suppress tumorigenesis via promotion of cell apoptosis. Subramanian and Shaha (72) suggested that an estrogen-induced increase in Ca²⁺ leads to ERK phosphorylation and, consequently, phosphorylation of cAMP responsive element binding protein 1, resulting in an increase in the expression of anti-apoptotic Bcl-2 protein. Furthermore, p38 has a role in cell survival and promotes increased levels of Bcl-2 and Bcl-xL in response to DNA damage and stress (73,74). The current study demonstrated that metformin-induced apoptosis may be mediated via downregulation of ERK, JNK and p38 phosphorylation, and Bcl-2 expression in AGS cells. Phosphorylation of MAPKs may be involved in Bcl-2 modulation in metformin-induced apoptosis of AGS cells. Additionally, metformin was previously reported to inhibit the invasion of human hepatocellular carcinoma cells via downregulation of ERK/JNK-mediated nuclear factor-κB-dependent signaling (75). The findings of the current study are in accordance with previous reports, and suggesting that metformin-suppressed cell growth is associated with AMPK-modulated AKT/mTOR and MAPK signaling pathways.

Wang et al (76) and Gao et al (77) have reported that metformin induces mitochondria-dependent apoptosis in human lung adenocarcinoma A549 cells and in human MDA-MB-231 and MDA-MB-435 breast cancer cells. Energy disruptors and AMPK activation lead to mitochondria-dependent apoptosis. Metformin is an energy disruptor and activator of AMPK (76,77). The current study investigated apoptosis induction and mitochondria-dependent pathway by ROS production, and the protein expression levels of pro- and anti-apoptotic proteins in metformin-treated AGS cells. The results suggest that metformin promotes caspase-dependent mitochondria-derived apoptosis in AGS cells and are in agreement with the previous study by Xiong et al (49).

Metformin has been established to exhibit clinical efficacy in conditions characterized by hyperinsulinemia, including polycystic ovarian syndrome, gestational diabetes, non-alcoholic steatohepatitis and pre-diabetes (78). Anticancer effects of metformin have been reported in various cancer types. In non-small cell lung cancer, metformin monotreatment or combined treatment resulted in decreased cell proliferation and increased apoptotic death (79). In colorectal cancer (CRC), metformin was demonstrated to interfere with the EMT process (80). Patients with T2D treated with metformin exhibited a lower rate of CRC than non-metformin users, with a statistically significant cumulative tumor-free survival (81). In breast cancer, cell growth was reduced by targeting the AMPK signaling pathway (82). The results of the present study suggested that metformin may be a promising therapy for human gastric adenocarcinoma and useful as an adjunct to other chemotherapies. There are two molecular actions of metformin can be implicated in anticancer actions (29): i) By decreasing insulinemia and glycemia action, metformin can block the PI3K/MAPKs signaling pathway, which are implicated in cancer cell growth (81); and ii) metformin can directly act on cancer cells by targeting various processes, including tumor cell metabolism, inflammation, angiogenesis and cancer stem cells, via the activation of the AMPK pathway (36,81). Metformin may become an alternative cancer adjuvant therapy, providing a novel approach for cancer prevention and treatment.

In conclusion, the findings of the current study provide an understanding of the mechanisms of metformin that can induce apoptosis of AGS cells through AMPK/AKT/mTOR signaling (Fig. 9). It is probable complete underlying mechanisms involved and the inhibitory effect of metformin on human gastric adenocarcinoma AGS cells have not been fully elucidated. The present study supports further research on the therapeutic use of metformin in treating human gastric cancer should be performed in the near future.

Funding

This study was supported by the project (grant no. TCRD107-55) from the Hualien Tzu Chi Hospital (Hualien, Taiwan) and in part by the China Medical University Hospital (Taichung, Taiwan; grant no. DMR-107-123).

Availability of data and materials

The data sets generated during the study are available from the corresponding author on reasonable request.

Authors’ contributions

CL, JY and HC conceived and designed the experiments. JC, YH and YJ performed the experiments. CL, FT and JY analyzed the data. CL, JY and HC wrote and modified the paper. All authors read and approved the final manuscript.

Ethics approval and consent

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.